Search

Displaying results 1861 - 1870 of 4212 in total
  1. Drug

    Tolevamer

    go.drugbank.com/drugs/DB01344
    Approved

    It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines.

  2. Drug

    Polyvinyl alcohol

    go.drugbank.com/drugs/DB11060
    Approved

    Polyvinyl alcohol is a water-soluble synthetic polymer obtained by polymerization of vinyl alcohol.

  3. Drug

    Dengue virus serotype 2

    go.drugbank.com/drugs/DB22665
    Approved

    [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  4. Drug

    Dengue virus serotype 3

    go.drugbank.com/drugs/DB22666
    Approved

    [A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.

  5. Drug

    Penicillamine

    go.drugbank.com/drugs/DB00859
    ApprovedInvestigational

    Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no a...

  6. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  7. Drug

    Acetic acid

    go.drugbank.com/drugs/DB03166
    ApprovedInvestigational

    (Stedman, 26th ed) Acetic acid otic (for the ear) is an antibiotic that treats infections caused by bacteria or fungus.

  8. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.

  9. Drug

    Meningococcal polysaccharide vaccine group C

    go.drugbank.com/drugs/DB13890
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.

  10. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the